Naloxone

"Naloxone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.

Descriptor ID	D009270
MeSH Number(s)	D03.132.577.249.706 D03.605.497.750 D03.633.400.686.750 D04.615.723.795.706
Concept/Terms	Naloxone Naloxone Nalone Nalone Naloxon Curamed Naloxon Curamed Curamed, Naloxon Naloxon-Ratiopharm Naloxon-Ratiopharm Naloxon Ratiopharm Naloxone Abello Naloxone Abello Abello, Naloxone Naloxone Hydrochloride Naloxone Hydrochloride Hydrochloride, Naloxone Naloxone Hydrochloride Dihydride Naloxone Hydrochloride Dihydride Dihydride, Naloxone Hydrochloride Hydrochloride Dihydride, Naloxone Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer Narcan Narcan Narcanti MRZ-2593 MRZ-2593 MRZ 2593 MRZ2593 MRZ 2593-Br MRZ 2593 Br MRZ 2593Br Naloxone Hydrobromide Naloxone Hydrobromide Hydrobromide, Naloxone

Below are MeSH descriptors whose meaning is more general than "Naloxone".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Naloxone [D03.132.577.249.706]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Naloxone [D03.605.497.750]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Naloxone [D03.633.400.686.750]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Naloxone [D04.615.723.795.706]

Below are MeSH descriptors whose meaning is related to "Naloxone".

Below are MeSH descriptors whose meaning is more specific than "Naloxone".

Naloxone
Buprenorphine, Naloxone Drug Combination
Naltrexone

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Naloxone" by people in this website by year, and whether "Naloxone" was a major or minor topic of these publications.

Bar chart showing 39 publications over 22 distinct years, with a maximum of 4 publications in 1999 and 2011 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	3	3
1997	0	1	1
1998	0	1	1
1999	1	3	4
2000	1	1	2
2002	0	1	1
2004	0	1	1
2005	0	1	1
2006	1	0	1
2008	0	2	2
2009	0	1	1
2010	0	2	2
2011	3	1	4
2012	0	1	1
2013	0	1	1
2016	0	1	1
2019	1	0	1
2021	0	2	2
2022	1	1	2
2023	0	1	1
2024	1	3	4
2025	1	1	2

Below are the most recent publications written about "Naloxone" by people in Profiles.

Shastry S, Carpenter J, Krotulski A, Brent J, Wax P, Aldy K, Campleman S, Culbreth R, Falise A, Hughes A, Hendrickson RG, Amaducci A, Judge B, Meaden C, Calello DP, Buchanan J, Shulman J, Levine M, Schwarz E, Manini AF. Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients. JAMA Netw Open. 2025 07 01; 8(7):e2518569.

View in: PubMed
Ovalles Lacruz A, Valle MS, Santoyo K, Clarke RD, Bhoite P, Alarcon LN. Empowering Future Physicians: Enhancing Naloxone Competency Through Early Harm Reduction Training in Medical Education. MedEdPORTAL. 2025; 21:11499.

View in: PubMed
Dicker F, Lothet E, Schwarz E, Aldy K, Brent J, Wax P, Culbreth R, Campleman S, Krotulski A, Logan B, Amaducci A, Judge B, Levine M, Calello D, Shulman J, Hughes A, Hendrickson RG, Meaden CW, Manini AF. Tramadol as a fentanyl adulterant: Prevalence and management in a ToxIC Fentalog study prospective cohort. Am J Emerg Med. 2025 03; 89:169-173.

View in: PubMed
Tatara E, Ozik J, Pollack HA, Schneider JA, Friedman SR, Harawa NT, Boodram B, Salisbury-Afshar E, Hotton A, Ouellet L, Mackesy-Amiti ME, Collier N, Macal CM. Agent-Based Model of Combined Community- and Jail-Based Take-Home Naloxone Distribution. JAMA Netw Open. 2024 12 02; 7(12):e2448732.

View in: PubMed
Aldy K, Krotulski A, Brent J, Campleman S, Culbreth R, Logan B, Wax P, Amaducci A, Judge B, Levine M, Schwarz E, Calello DP, Meaden CW, Shulman J, Hughes A, Hendrickson R, Carpenter J, Buchanan J, Manini AF. Emergency Department Patients with Para-Fluorofentanyl Overdose. J Emerg Med. 2025 May; 72:56-69.

View in: PubMed
Abbasloo E, Esmaeili-Mahani S, Kobeissy F, Currier Thomas T. Evidence for the Induction of Analgesic Cross-Tolerance Between Opioid and Apelin/APJ Systems in Male Rats. J Stud Alcohol Drugs. 2024 Sep; 85(5):704-712.

View in: PubMed
Tabatabai M, Cooper RL, Wilus DM, Edgerton RD, Ramesh A, MacMaster SA, Patel PN, Singh KP. The Effect of Naloxone Access Laws on Fatal Synthetic Opioid Overdose Fatality Rates. J Prim Care Community Health. 2023 Jan-Dec; 14:21501319221147246.

View in: PubMed
Livingston CJ, Berenji M, Titus TM, Caplan LS, Freeman RJ, Sherin KM, Mohammad A, Salisbury-Afshar EM. American College of Preventive Medicine: Addressing the Opioid Epidemic Through a Prevention Framework. Am J Prev Med. 2022 09; 63(3):454-465.

View in: PubMed
Bounthavong M, Shayegani R, Manning JM, Marin J, Spoutz P, Hoffman JD, Harvey MA, Himstreet JE, Kay CL, Freeman BA, Almeida A, Christopher MLD. Comparison of virtual to in-person academic detailing on naloxone prescribing rates at three U.S. Veterans Health Administration regional networks. Int J Med Inform. 2022 05; 161:104712.

View in: PubMed
Santiago D, Rosario Y, Melin K, Duconge J, Roman L, Gonzalez A, Venkataramanan R. Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study. P R Health Sci J. 2021 12; 40(4):192-194.

View in: PubMed

People

Explore

Similar Concepts

Top Journals